August 08, 2023 – Everest Pharma is proud to announce the launch of RUXOTOR Cream, a generic version of the FDA-approved OPZELURA (Ruxolitinib Cream 1.5%), offering a significant advancement in the topical treatment of non-segmental vitiligo and mild-to-moderate atopic dermatitis.
The availability of RUXOTOR CREAM (Generic of OPZELURA) is expected to strengthen Everest Pharma in its position as a pioneer in dermatologic care and high-quality topical therapies.
About Everest Pharma:
Everest Pharma is a globally recognized pharmaceutical company committed to offering high-quality, affordable generic medicines. With a focus on innovation and access, the company continues to develop essential therapies across a range of therapeutic areas to improve patient outcomes worldwide.
For more information on RUXOTOR CREAM and Everest Pharma’s portfolio, visit https://www.ruxotor.com/ or https://www.everestpharmabd.com/
